---
title: The Effect of Meal Composition on Blood Lipids
nct_id: NCT02529709
overall_status: COMPLETED
phase: NA
sponsor: Texas Christian University
study_type: INTERVENTIONAL
primary_condition: Dyslipidemia
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02529709.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02529709"
ct_last_update_post_date: 2016-04-21
last_seen_at: "2026-05-12T06:36:37.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Meal Composition on Blood Lipids

**Official Title:** The Effect of Meal Composition on Blood Lipid Concentrations

**NCT ID:** [NCT02529709](https://clinicaltrials.gov/study/NCT02529709)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 24
- **Lead Sponsor:** Texas Christian University
- **Conditions:** Dyslipidemia
- **Start Date:** 2015-10
- **Completion Date:** 2016-04
- **CT.gov Last Update:** 2016-04-21

## Brief Summary

The purpose of this study is to see if a high-protein meal leads to a better postprandial (after a meal) blood lipid profile compared to a high-monounsaturated meal.

## Detailed Description

The effect of a high-protein diet compared to a high-monounsaturated fat diet on fasting lipids is controversial (1,2), In addition, these studies did not examine the effect of a high-protein compared to a high-monounsaturated meal on postprandial lipid concentrations. Postprandial lipid responses are important to examine since they are associated with heart disease (3,4). In addition, most individuals in Western countries are in a postprandial state for majority of the day. The present study will compare the effect of a high-protein meal versus a high-monounsaturated fat meal on postprandial lipid responses.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Men and women ages 18-65 years.

Exclusion Criteria:

* Use of medications or supplements that affect lipid levels, body weight, or blood glucose,
* following a weight loss diet,
* being a vegan,
* smoking,
* heavy alcohol use,
* pregnancy,
* lactation,
* severe depression,
* eating disorders,
* presence of liver, kidney, gastrointestinal, adrenal, or untreated thyroid disease,
* diabetes,
* lactose intolerance,
* documented mal-absorption, or
* bowel surgery that affects absorption.
```

## Arms

- **High-protein meal condition** (EXPERIMENTAL)
- **High-monounsaturated fat meal condition** (ACTIVE_COMPARATOR)

## Interventions

- **High-Protein Condition** (OTHER) — The participants will be fed a high-protein meal
- **High-Monounsaturated Fat Condition** (OTHER) — The participants will be fed a high-monounsaturated fat meal

## Primary Outcomes

- **Blood lipid concentrations.** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_

## Secondary Outcomes

- **IL-6** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_
- **TNF-α** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_
- **C-reactive protein** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_
- **GLP-1** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_
- **Insulin** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_
- **Glucagon** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_
- **Glucose** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_
- **Leptin** _(time frame: At 0 minute before the meal begins and at 30, 60, 120, and 180 minutes after the meal begins)_

## Locations (1)

- Texas Christian University, Fort Worth, Texas, United States

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `locations.texas christian university|fort worth|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02529709.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02529709*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*